CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 952 enrolled
Drug / intervention
DaTscandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01141023
NCT01141023Phase 2Completed
CompareCT.gov

The Parkinson's Progression Markers Initiative (PPMI)

Ken Marek, MD·interventional·Posted Jun 10, 2010·Updated Nov 14, 2023

In Brief

A Phase 2 clinical trial evaluating DaTscan for Parkinson Disease. Completed, enrolled 952 participants across 34 sites in 11 countries.

Detailed Summary

This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesAustralia, Austria, France, Germany, Greece, Israel, Italy, Norway, Spain, United Kingdom, United States
CollaboratorsInstitute for Neurodegenerative Disorders

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 10, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 16.1 years ago

Interventions

DaTscandrug